Moderna, After Losing US Funding, Rebounds to Start mRNA Bird Flu Vaccine Trial

Why It Matters

The vaccine addresses a looming pandemic threat while demonstrating the mRNA platform’s adaptability, and it could generate a new revenue stream for Moderna despite recent federal funding cuts.

Key Takeaways

• Moderna launched Phase 3 trial enrolling ~4,000 adults in US/UK.
• mRNA‑1018 targets H5 bird flu, using COVID‑19 platform.
• CEPI contributed $54.3 M after US funding cut.
• Vaccine could secure low‑cost supply for low‑income nations.
• Success may restore FDA confidence after earlier rejection.

Pulse Analysis

Moderna’s decision to press ahead with mRNA‑1018 underscores the resilience of the mRNA platform beyond COVID‑19. The H5 subtype of avian influenza has sporadically infected humans, and a pandemic‑grade vaccine could fill a glaring gap in global preparedness. After the Trump administration terminated a $766 million contract—comprising a $176 million 2024 award and a $590 million 2025 extension—Moderna faced a sudden funding vacuum. Yet the company leveraged its existing flu‑vaccine data to move directly into a Phase 3 safety and immunogenicity study involving roughly 4,000 volunteers in the United States and the United Kingdom.

With federal dollars withdrawn, the Coalition for Epidemic Preparedness Innovations stepped in, pledging up to $54.3 million to keep the program afloat. The agreement obligates Moderna to reserve 20 percent of its mRNA manufacturing lines for affordable bird‑flu doses destined for low‑ and middle‑income markets. This public‑private partnership not only mitigates the immediate cash shortfall but also positions Moderna as a key supplier in a tiered‑access model, potentially unlocking future financing from global health agencies and expanding its footprint in emerging economies.

If the Phase 3 data confirm robust immunogenicity and an acceptable safety profile, Moderna will likely file a Biologics License Application before the end of 2026. A successful approval could restore confidence after the FDA’s earlier refusal and generate a new revenue stream estimated at several hundred million dollars annually, especially during seasonal flu seasons when the vaccine could be co‑administered. Moreover, the trial validates the broader strategy of repurposing mRNA technology for rapidly evolving pathogens, reinforcing investor sentiment and encouraging further public‑sector collaborations on next‑generation vaccines.